This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Low, J. A. Articles by Swain, S. M. Search for Related Content PubMed PubMed Citation Articles by Low, J. A. Articles by Swain, S. M. Social Bookmarking                            What's this?

Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy

From the Cancer Therapeutics Branch, Medical Oncology Clinical Research Unit, Biostatistics and Data Management Section, and Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and Department of Medicine, University of Michigan, Ann Arbor, MI

Address reprint requests to Sandra M. Swain, MD, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889-5015; e-mail: swains{at}mail.nih.gov

PURPOSE: To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy.

PATIENTS AND METHODS: Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC). Patients were treated to best response with cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen. Patients with pathologic complete response received definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent mastectomy, lymph node dissection, and radiotherapy. All patients underwent six additional cycles of adjuvant chemotherapy.

RESULTS: OS and EFS were obtained with a median live patient follow-up time of 16.8 years. The 46 IBC patients had a median OS of 3.8 years and EFS of 2.3 years, compared with 12.2 and 9.0 years, respectively, in stage IIIA breast cancer patients. Fifteen-year OS survival was 20% for IBC versus 50% for stage IIIA patients and 23% for stage IIIB non-IBC. Pathologic response was not associated with improved survival for stage IIIA or IBC patients. Presence of dermal lymphatic invasion did not change the probability of survival in clinical IBC patients.

CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook.

Preliminary portions of this work were presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002 (abstract 251).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Molckovsky, B. Fitzgerald, O. Freedman, R. Heisey, and M. Clemons Approach to inflammatory breast cancer Can Fam Physician, January 1, 2009; 55(1): 25 - 31. [Abstract] [Full Text] [PDF]

				S. X. Yang, S. M. Steinberg, D. Nguyen, T. D. Wu, Z. Modrusan, and S. M. Swain Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5893 - 5899. [Abstract] [Full Text] [PDF]

				S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, P. LoRusso, D. P. Lombardi, S. Ben Ahmed, D. L. Citrin, M. L. DeSilvio, et al. Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy J. Clin. Oncol., March 1, 2008; 26(7): 1066 - 1072. [Abstract] [Full Text] [PDF]

				S. I. Labidi, K. Mrad, A. Mezlini, M. A. Ouarda, J. D. Combes, M. B. Abdallah, K. B. Romdhane, P. Viens, and F. B. Ayed Inflammatory breast cancer in Tunisia in the era of multimodality therapy Ann. Onc., March 1, 2008; 19(3): 473 - 480. [Abstract] [Full Text] [PDF]

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				R. G. Ancheta, H. Lewin, J. Said, and S. A. Hurvitz Primary Dural Marginal Zone Lymphoma in a Woman With Inflammatory Breast Cancer J. Clin. Oncol., January 10, 2008; 26(2): 326 - 328. [Full Text] [PDF]

				B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al. Trends for Inflammatory Breast Cancer: Is Survival Improving? Oncologist, August 1, 2007; 12(8): 904 - 912. [Abstract] [Full Text] [PDF]

				P. F. Escobar, R. J. Patrick, L. A. Rybicki, D. Hicks, D. E. Weng, and J. P. Crowe Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer Ann. Surg. Oncol., June 1, 2006; 13(6): 783 - 787. [Abstract] [Full Text] [PDF]

				S. J. Van Laere, I. Van der Auwera, G. G. Van den Eynden, H. J. Elst, J. Weyler, A. L. Harris, P. van Dam, E. A. Van Marck, P. B. Vermeulen, and L. Y. Dirix Nuclear Factor-{kappa}B Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-{kappa}B DNA-Binding. Clin. Cancer Res., June 1, 2006; 12(11): 3249 - 3256. [Abstract] [Full Text] [PDF]

				H. K. Dressman, C. Hans, A. Bild, J. A. Olson, E. Rosen, P. K. Marcom, V. B. Liotcheva, E. L. Jones, Z. Vujaskovic, J. Marks, et al. Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy Clin. Cancer Res., February 1, 2006; 12(3): 819 - 826. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95 J. Clin. Oncol., January 20, 2006; 24(3): 370 - 378. [Abstract] [Full Text] [PDF]

				D. A. Stewart, A. H. G. Paterson, J. D. Ruether, J. Russell, P. Craighead, M. Smylie, and J. Mackey High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study Ann. Onc., September 1, 2005; 16(9): 1463 - 1468. [Abstract] [Full Text] [PDF]

				M. Panades, I. A. Olivotto, C. H. Speers, T. Shenkier, T. A. Olivotto, L. Weir, S. J. Allan, and P. T. Truong Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis J. Clin. Oncol., March 20, 2005; 23(9): 1941 - 1950. [Abstract] [Full Text] [PDF]